{
    "clinical_study": {
        "@rank": "5045", 
        "acronym": "Q-CAMP", 
        "arm_group": [
            {
                "arm_group_label": "Training set", 
                "description": "Data from subjects in the training set will be utilized to further develop the vascuCAPTM classifiers."
            }, 
            {
                "arm_group_label": "Testing set", 
                "description": "Data from subjects in the testing set will be used to assess the study endpoints."
            }
        ], 
        "biospec_descr": {
            "textblock": "After endarterectomy during surgery, the excised plaque specimens will be sent to the\n      hospital's pathology lab to be analyzed."
        }, 
        "biospec_retention": "Samples Without DNA", 
        "brief_summary": {
            "textblock": "The investigators use MRI to evaluate the extent, as well as, the structure, composition,\n      and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in\n      patients scheduled to undergo an endarterectomy of the aforementioned vascular beds as part\n      of their routine clinical care."
        }, 
        "brief_title": "Q-CAMP: Quantitative CArdiovascular Magnetic Resonance Imaging and Profiling of Atherosclerotic Lesions", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": [
            "Carotid Atherosclerosis", 
            "Peripheral Arterial Disease"
        ], 
        "condition_browse": {
            "mesh_term": [
                "Atherosclerosis", 
                "Peripheral Arterial Disease", 
                "Peripheral Vascular Diseases", 
                "Carotid Artery Diseases"
            ]
        }, 
        "detailed_description": {
            "textblock": "The investigators hypothesize that in vivo MRI examinations of patients, when suitably\n      acquired and analyzed with the vascuCAP\u2122 analysis software, can provide a sufficiently\n      accurate profile of plaque characteristics to provide an objective basis for patient\n      management.  Study subjects include patients undergoing endarterectomies to mitigate their\n      clinical risk or symptoms for conditions including stroke, claudication, and critical limb\n      ischemia. The endarterectomy specimens removed at surgery will allow a direct comparison\n      between the MRI information obtained prior to the surgery and the histopathological analyses\n      of the arterial specimens. The vascuCAPTM measurements of structural and functional features\n      of the arterial wall will be performed in patients undergoing endarterectomy. Measured\n      results will be compared in a blinded fashion with histology to assess performance of plaque\n      profiling and build a pilot prediction model for risk scoring."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n        Individuals must meet one of the following inclusion criteria in order to be eligible to\n        participate in the study:\n\n          -  Case subjects will be patients with documented carotid atherosclerosis, scheduled for\n             magnetic resonance angiography and subsequent elective endarterectomy with 30 days of\n             enrollment in the study\n\n          -  Case subjects will be patients with peripheral arterial disease (PAD) with clinical\n             symptoms, scheduled for magnetic resonance angiography and indicated endarterectomy\n             of diseased areas of femoral arteries within 30 days of enrollment in the study\n\n        Exclusion Criteria:\n\n          -  Subjects with claustrophobia or inability to tolerate prior MRI studies.\n\n          -  Subjects with metal implants that are not MRI compatible (LSU detailed checklist to\n             be attached) including: Subjects with any type of bio-implant activated by\n             mechanical, electronic, or magnetic means (e.g. cochlear implants, pacemakers,\n             neurostimulators, biostimulators, electronic infusion pumps, etc.). Subjects with any\n             type of ferromagnetic bio-implant that could potentially be displaced or damaged,\n             such as aneurysm clips, metallic skull plates, etc.\n\n          -  Subjects with a history of kidney disease or dialysis that are unable to receive\n             intravenous gadolinium contrast material.\n\n          -  Female subjects. A urine pregnancy test will be required of all female subjects of\n             childbearing potential prior to inclusion in this study. Pregnant or nursing females\n             will be excluded from the study.\n\n          -  Subjects who cannot adhere to the experimental protocol.\n\n          -  Subjects allergic to gadolinium contrast material."
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years", 
            "sampling_method": "Non-Probability Sample", 
            "study_pop": {
                "textblock": "Individuals must meet one of the following inclusion criteria in order to be eligible to\n        participate in the study:\n\n          -  Case subjects will be patients with documented carotid atherosclerosis, scheduled for\n             magnetic resonance angiography and subsequent elective endarterectomy with 30 days of\n             enrollment in the study\n\n          -  Case subjects will be patients with peripheral arterial disease (PAD) with clinical\n             symptoms, scheduled for magnetic resonance angiography and indicated endarterectomy\n             of diseased areas of femoral arteries within 30 days of enrollment in the study"
            }
        }, 
        "enrollment": {
            "#text": "150", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 15, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02143102", 
            "org_study_id": "305"
        }, 
        "is_fda_regulated": "No", 
        "lastchanged_date": "May 19, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Marrero", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70072"
                    }, 
                    "name": "West Jefferson Medical Center"
                }
            }, 
            {
                "facility": {
                    "address": {
                        "city": "New Orleans", 
                        "country": "United States", 
                        "state": "Louisiana", 
                        "zip": "70112"
                    }, 
                    "name": "LSU ILH"
                }, 
                "investigator": {
                    "last_name": "Malachi Sheahan, M.D.", 
                    "role": "Principal Investigator"
                }, 
                "status": "Not yet recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_groups": "2", 
        "official_title": "Quantitative Cardiovascular Magnetic Resonance Imaging and Profiling of Atherosclerotic Lesions", 
        "overall_contact": {
            "email": "MSHEAH@LSUHSC.EDU", 
            "last_name": "Malachi Sheahan, M.D.", 
            "phone": "(504) 412-1960"
        }, 
        "overall_official": {
            "affiliation": "Elucid Biomaging Inc.", 
            "last_name": "Andrew J. Buckler, M.S.", 
            "role": "Study Director"
        }, 
        "overall_status": "Not yet recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "N/A", 
        "primary_completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": {
            "description": "We use MRI to evaluate the extent, as well as, the structure, composition, and functional aspects of atherosclerotic plaques in human carotid and femoral arteries in patients scheduled to undergo an endarterectomy of the aforementioned vascular beds as part of their routine clinical care. The endarterectomy specimens removed at surgery will allow a direct comparison between the MRI information obtained prior to the surgery and the histopathological analyses of the arterial specimens. The vascuCAPTM measurements of structural and functional features of the arterial wall will be performed in patients undergoing endarterectomy. Measured results will be compared in a blinded fashion with histology to assess performance of plaque profiling.", 
            "measure": "Bias, precision, and reproducibility of plaque as assessed by MRI relative to histopathology as ground truth.", 
            "safety_issue": "No", 
            "time_frame": "Assessed on tissue samples collected within 30 days of MRI"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02143102"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "Classify the target lesion according to whether the analytes suggest it is not a plaque, or if it is, which of the 8 AHA types best fits the analyte profile.  for each of the AHA types according to histopathology, we will report the frequency with which vascuCAPTM's classification agrees with histopathology.", 
            "measure": "Accuracy of plaque type characterization by MRI as compared to histopathology as ground truth", 
            "safety_issue": "No", 
            "time_frame": "Assessed on tissue samples collected within 30 days of MRI"
        }, 
        "source": "Elucid Bioimaging Inc.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Elucid Bioimaging Inc.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "June 2014", 
        "study_design": "Observational Model: Cohort, Time Perspective: Prospective", 
        "study_type": "Observational", 
        "verification_date": "May 2014"
    }
}